JAKAVI demonstrated overall survival benefit in patients with MF1
At 5-year follow-up, patients randomised to JAKAVI arm had improved overall survival compared with patients treated with BAT1
COMFORT-II: Overall survival at 5-year follow-up of JAKAVI vs BAT1

Adapted from Verstovsek S et al. A pooled overall survival (OS) Analysis of 5-Year data from the COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of myelofibrosis (MF). Blood. 2016;128(22):3110.
- Of the 227 patients originally randomised to BAT, 69.6% crossed over to JAKAVI during the study. In the ITT analysis of overall survival, patients who crossed over from the BAT arm to receive JAKAVI were included in the BAT group2
- Median OS was 5.3 years in the JAKAVI arm compared with 3.8 years in the total control arm. After adjusting for crossover using an RPSFT model, there was a 65% reduction in risk of death with JAKAVI (HR=0.35; 95% CI, 0.23-0.59)2
JAKAVI is the only MF therapy that is associated with a survival benefit3
COMFORT I
- There was a ~30% reduction in risk of death with JAKAVI compared with placebo (HR=0.69; 95% CI, 0.50-0.96; P=0.025)4
COMFORT II
- Survival benefit with JAKAVI was evident at just 2 years (HR=0.52; 95% CI, 0.27-0.99; P=0.041)3
- At 3.5 years, JAKAVI treatment was associated with a 65% reduction in risk of death vs BAT (HR=0.58; 95% CI, 0.36-0.93; P=0.02)5
- At 5-year followup, there was a 33% reduction in risk of death with JAKAVI compared with BAT by ITT analysis (HR=0.67; 95% CI, 0.44-1.02; P=0.06)6
JAKAVI improved overall survival compared with placebo at 5-year follow-up4
- At 1-year follow-up (median: 52 and 51 weeks), JAKAVI demonstrated survival improvement (HR=0.50; 95% CI, 0.25-0.98; P=0.04)3
- At 2-year follow-up (median: 102 weeks), JAKAVI demonstrated improved overall survival compared with placebo (HR=0.58; 95% CI, 0.36-0.95; P=0.028)3
- At 3-year follow-up (median: 149 weeks), JAKAVI improved overall survival compared with placebo (HR=0.69; 95% CI, 0.46-1.03; P=0.067)7
JAKAVI continues to provide survival improvement consistent with that observed in earlier analyses2